Merck KGaA In The Market For Bolt-On M&A
Will Have €5bn-€9bn To Invest By End of 2022
Executive Summary
Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."
You may also be interested in...
Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate
The Paris-based biotech was chosen to take the compound forward, with Merck KGaA also taking a stake in the company.
Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.